MedTrace Logo

The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer

NCT04991129 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-06-26

No results posted yet for this study

Summary

A clinical study of WJ01024 in subjects with advanced cancer in China, to evaluate the safety, tolerability, PK and efficacy of WJ01024. This study includes a dose escalation part and a dose expansion part. Patients receive WJ01024 on Day 1 and Day 3 of each week, 4 weeks as a cycle, until disease progression, or intolerable toxicity , withdrawal of consent, or end of the study, whichever occurs first.

Conditions

Interventions

DRUG

WJ01024

5mg QD: WJ01024, Q4W, once per day

DRUG

WJ01024

5mg BID: WJ01024, Q4W, twice per day

DRUG

WJ01024

10mg BID: WJ01024, Q4W, twice per day

DRUG

WJ01024

40mg BIW: WJ01024, Q4W, twice per week

DRUG

WJ01024

60mg BIW: WJ01024, Q4W, twice per week

DRUG

WJ01024

80mg BIW: WJ01024, Q4W, twice per week

DRUG

WJ01024

60mg QW: WJ01024, Q4W, once per week

DRUG

WJ01024

80mg QW: WJ01024, Q4W, once per week

DRUG

WJ01024

50mg QW: WJ01024, Q4W, once per week

DRUG

WJ01024

40mg QW: WJ01024, Q4W, once per week

Sponsors & Collaborators

  • Suzhou Junjing BioSciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ruihua Xu, MD · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2025-05-28
Completion
2025-05-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04991129 on ClinicalTrials.gov